Monoclonal Antibody (Mab) sB24M

N/A

Report date: 2023/07/21 16:48:46

Base Information

Drug NameMonoclonal Antibody (Mab) sB24M
Drug Alias NameMonoclonal Antibody (Mab) sB24M (SWISS BIOPHARMA MED)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionTumor necrosis factor α inhibitorsCluster of differentiation 47 inhibitors
TargetsTumor necrosis factor αCluster of differentiation 47
Therapy Area/IndicationsPyoderma GangrenosumPyoderma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelarusLatvia
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesSwiss Biopharma Med GmbH
China Registration ClassN/A

Develop Information

Active CompaniesSwiss Biopharma Med GmbH
Inactive CompaniesN/A
Active IndicationsPyoderma GangrenosumPyoderma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A